Cargando…

Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease

OBJECTIVE: To find the combination of candidate biomarkers and cognitive endpoints to maximize statistical power and minimize cost of clinical trials of healthy elders at risk for cognitive decline due to Alzheimer's disease. METHODS: Four-hundred and twelve cognitively normal participants were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Insel, Philip S, Mattsson, Niklas, Mackin, R Scott, Kornak, John, Nosheny, Rachel, Tosun-Turgut, Duygu, Donohue, Michael C, Aisen, Paul S, Weiner, Michael W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435707/ https://www.ncbi.nlm.nih.gov/pubmed/26000325 http://dx.doi.org/10.1002/acn3.192

Ejemplares similares

Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information
por: Insel, Philip S., et al.
Publicado: (2016)

Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease
por: Mattsson, Niklas, et al.
Publicado: (2013)

Study partner‐reported decline identifies cognitive decline and dementia risk
por: Nosheny, Rachel L., et al.
Publicado: (2019)

CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
por: Mattsson, N, et al.
Publicado: (2013)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults
por: Insel, Philip S., et al.
Publicado: (2020)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
por: Insel, Philip S., et al.
Publicado: (2017)

Determining clinically meaningful decline in preclinical Alzheimer disease
por: Insel, Philip S., et al.
Publicado: (2019)

Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention
por: Insel, Philip S, et al.
Publicado: (2020)

Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease
por: Insel, Philip S., et al.
Publicado: (2023)

Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia: Results from the Brain Health Registry
por: Mackin, R. Scott, et al.
Publicado: (2018)

Online study partner-reported cognitive decline in the Brain Health Registry
por: Nosheny, Rachel L., et al.
Publicado: (2018)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Early Indications of Future Cognitive Decline: Stable versus Declining Controls
por: Rizk-Jackson, Angela, et al.
Publicado: (2013)

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
por: Ossenkoppele, Rik, et al.
Publicado: (2019)

Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
por: Cullen, Nicholas C., et al.
Publicado: (2020)

Poor Sleep Quality and Daytime Fatigue Are Associated With Subjective but Not Objective Cognitive Functioning in Clinically Relevant Hoarding
por: Nutley, Sara K., et al.
Publicado: (2021)

Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
por: Tosun, Duygu, et al.
Publicado: (2021)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease
por: Li, Dan, et al.
Publicado: (2019)

Differences in Prefrontal, Limbic, and White Matter Lesion Volumes According to Cognitive Status in Elderly Patients with First-Onset Subsyndromal Depression
por: Lee, Jun-Young, et al.
Publicado: (2014)

Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition
por: Vemuri, Prashanthi, et al.
Publicado: (2011)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Unsupervised Performance of the CogState Brief Battery in the Brain Health Registry: Implications for Detecting Cognitive Decline
por: Banh, T., et al.
Publicado: (2022)

Evidence for age-associated cognitive decline from Internet game scores
por: Geyer, Jason, et al.
Publicado: (2015)

Multimodal MRI-based imputation of the Aβ+ in early mild cognitive impairment
por: Tosun, Duygu, et al.
Publicado: (2014)

β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly
por: Svenningsson, Anna L., et al.
Publicado: (2019)

Different associations of white matter lesions with depression and cognition
por: Lee, Jun-Young, et al.
Publicado: (2012)

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome
por: Rafii, Michael S., et al.
Publicado: (2015)

Hoarding symptoms are associated with higher rates of disability than other medical and psychiatric disorders across multiple domains of functioning
por: Nutley, Sara K., et al.
Publicado: (2022)

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
por: Weiner, Michael W., et al.
Publicado: (2017)

Biomarkers for Microglial Activation in Alzheimer's Disease
por: Lautner, Ronald, et al.
Publicado: (2011)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Predicting the course of Alzheimer’s progression
por: Iddi, Samuel, et al.
Publicado: (2019)

Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease
por: Baldaranov, Dobri, et al.
Publicado: (2023)

Plasma tau in Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Association of Sleep and β-Amyloid Pathology Among Older Cognitively Unimpaired Adults
por: Insel, Philip S., et al.
Publicado: (2021)

Remote blood collection from older adults in the Brain Health Registry for plasma biomarker and genetic analysis
por: Fockler, Juliet, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ub2fdltqp7idgoiqn5j62019mc